2021
How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome
Sethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome. British Journal Of Haematology 2021, 195: 352-364. PMID: 33987825, DOI: 10.1111/bjh.17458.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntineoplastic AgentsBexaroteneBiomarkers, TumorClinical Trials as TopicCombined Modality TherapyDelayed DiagnosisDiagnosis, DifferentialElectronsHematopoietic Stem Cell TransplantationHistone Deacetylase InhibitorsHumansInterferon-alphaMaleMycosis FungoidesNeoplasm StagingNeoplastic Stem CellsPhotopheresisPrognosisPUVA TherapyRetinoidsSezary SyndromeSignal TransductionSkin NeoplasmsT-Lymphocyte SubsetsConceptsT-cell lymphomaSézary syndromeMultidisciplinary careCutaneous T-cell lymphoma mycosis fungoidesMycosis fungoides/Sézary syndromeCutaneous T-cell lymphomaLines of therapyAdditional treatment optionsNon-Hodgkin lymphomaDuration of useCumulative drug toxicityEarly referralRecurrent diseaseDiagnostic delayPatients' qualityTreatment optionsCommon subtypeTreatable diseaseRare subsetDrug toxicityLymphomaSyndromeDiseasePresent reviewCare
2017
CMET-09. PAN-CANCER PROFILES OF BRAIN METASTASES: PRIORITIZATION OF THERAPEUTIC TARGETS
Ferguson S, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos P, Kesari S, Hu J, Rudnick J, Salacz M, Piccioni D, Suyun H, Davies M, Glitza I, Heymach J, Zhang J, Ibrahim N, de Groot J, McCarty J, O’Brien B, Sawaya R, Verhaak R, Reddy S, Priebe W, Spetzler D, Heimberger A. CMET-09. PAN-CANCER PROFILES OF BRAIN METASTASES: PRIORITIZATION OF THERAPEUTIC TARGETS. Neuro-Oncology 2017, 19: vi40-vi41. PMCID: PMC5692786, DOI: 10.1093/neuonc/nox168.158.Peer-Reviewed Original ResearchBrain metastasesNon-small cell lung cancerBreast cancer brain metastasesMelanoma brain metastasesNSCLC brain metastasesCancer brain metastasesAdditional treatment optionsBrain metastasis treatmentCell lung cancerPrimary cancer specimensTumor histologyPrimary tumorTreatment optionsLung cancerMetastasis samplesBreast cancerMetastasis treatmentCancer specimensTherapeutic targetMetastasisTumor profilingDNA synthesisExpression frequencyProtein expressionPotential targetCurrent and Emerging Drug Therapies in Chronic Lymphocytic Leukemia
Sethi T, Reddy N. Current and Emerging Drug Therapies in Chronic Lymphocytic Leukemia. TouchREVIEWS In Oncology & Haematology 2017, 13: 34. DOI: 10.17925/ohr.2017.13.01.34.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsB cell receptorDrug therapyCLL therapyChronic lymphocytic leukemia patientsElderly unfit patientsAdditional treatment optionsDuration of treatmentRepertoire of drugsImmune effector responsesLymphocytic leukemia patientsChronic lymphocytic leukemiaLong-term toxicityUnfit patientsPatient ageCD20 antibodyRisk stratificationCLL treatmentAsymptomatic individualsTherapy optionsTreatment optionsEffector responsesLeukemia patientsLymphocytic leukemiaCLL cellsTreatment approaches
2016
Barriers to participation in industry‐sponsored clinical trials in pediatric type 2 diabetes
Farrell R, Bethin K, Klingensmith G, Tamborlane WV, Gubitosi‐Klug R. Barriers to participation in industry‐sponsored clinical trials in pediatric type 2 diabetes. Pediatric Diabetes 2016, 18: 574-578. PMID: 27807915, DOI: 10.1111/pedi.12465.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAttitude of Health PersonnelChildDiabetes Mellitus, Type 2Drug ApprovalDrug IndustryDrugs, InvestigationalEndocrinologyHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInternetNeeds AssessmentPatient SelectionPediatricsRandomized Controlled Trials as TopicResearch PersonnelResearch Support as TopicSocieties, ScientificSurveys and QuestionnairesUnited StatesUnited States Food and Drug AdministrationWorkforceConceptsPediatric Endocrine SocietyType 2 diabetesClinical trialsPediatric endocrinologistsIndustry-sponsored clinical trialsPatients age 18 yearsPediatric type 2 diabetesCurrent glycemic controlNew T2D casesAdditional treatment optionsAge 18 yearsBaseline demographicsT2D patientsGlycemic controlMedication useMultiple medicationsPediatric patientsResearch nursesPediatric populationTreatment optionsEndocrine SocietyT2D casesDrug AdministrationVisit scheduleAnonymous online survey
2014
Two‐year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: Final results of the RNS System Pivotal trial
Heck CN, King‐Stephens D, Massey AD, Nair DR, Jobst BC, Barkley GL, Salanova V, Cole AJ, Smith MC, Gwinn RP, Skidmore C, Van Ness PC, Bergey GK, Park YD, Miller I, Geller E, Rutecki PA, Zimmerman R, Spencer DC, Goldman A, Edwards JC, Leiphart JW, Wharen RE, Fessler J, Fountain NB, Worrell GA, Gross RE, Eisenschenk S, Duckrow RB, Hirsch LJ, Bazil C, O'Donovan CA, Sun FT, Courtney TA, Seale CG, Morrell MJ. Two‐year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: Final results of the RNS System Pivotal trial. Epilepsia 2014, 55: 432-441. PMID: 24621228, PMCID: PMC4233950, DOI: 10.1111/epi.12534.Peer-Reviewed Original ResearchConceptsIntractable partial-onset seizuresPartial-onset seizuresOpen-label periodResponsive stimulationSeizure focusSeizure reductionOnset seizuresSham stimulationIntractable partial onset epilepsySerious adverse event ratesFocal cortical stimulationPartial-onset epilepsyAdverse event ratesFrequency of seizuresMedian percent reductionAdditional treatment optionsSham stimulation groupBlinded periodMonth postimplantAdjunctive therapyAdverse eventsOnset epilepsyPivotal trialsCortical stimulationTreatment options
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply